Shopping Cart
Remove All
Your shopping cart is currently empty
PD-L1-IN-6 (Compound 16) targets STAT3, with a KD of 90.5 nmol/L, to inhibit the expression of PD-L1 in neutrophils. It enhances the antifungal immune response mediated by neutrophils and is effective when administered orally.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | PD-L1-IN-6 (Compound 16) targets STAT3, with a KD of 90.5 nmol/L, to inhibit the expression of PD-L1 in neutrophils. It enhances the antifungal immune response mediated by neutrophils and is effective when administered orally. |
| In vitro | PD-L1-IN-6 (40 μM) inhibits PD-L1 expression by 80.17% without significant cytotoxicity to neutrophils. It exhibits slight permeability across the blood-brain barrier, with p e measured at 1.22×10^-6 cm/s. |
| In vivo | PD-L1-IN-6 (50-100 mg/kg, oral administration, 3 days) suppresses β-glucan-induced CXCL1 and CXCL2 secretion in a C57BL/6 mouse model infected with C. albicans, promoting neutrophil migration and enhancing neutrophil-mediated antifungal immunity. |
| Formula | C21H24Cl2O6S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.